Project Details
Description
A Phase I clinical study to evaluate the safety, tolerability, and immunogenicity of SARS-CoV-2 variant (Omicron) mRNA vaccine which is used to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
| Status | Finished |
|---|---|
| Effective start/end date | 22/08/22 → 25/08/23 |
Collaborative partners
- Suzhou Abogen Biosciences Co., Ltd. (lead)
Keywords
- Omicron
- COVID-19
- Pneumonia, Viral
- Pneumonia
- Respiratory Tract Infections
- Infections
- Virus Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Lung Diseases
- Respiratory Tract Diseases
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.